Navigation Links
ClinicalKey Key Innovator Award to Recognize the Innovative Use of Health Information and Technology to Save and Improve Lives
Date:11/28/2012

PHILADELPHIA, November 28, 2012 /PRNewswire/ --

Nominations open to hospitals, medical schools and healthcare institutions through Dec. 31

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today that it will award a $10,000 grant to a U.S.-based hospital, medical school or institution that has demonstrated the most innovative use of information and technology to save lives and improve patient care.

The Key Innovator Award is sponsored by Elsevier's ClinicalKey, the world's first clinical insight engine designed specifically to help physician's quickly locate relevant clinical responses that address their specific health care needs.

"Both information and technology are critically important to healthcare and many times make the difference between life and death," noted Jim Donohue, Managing Director for Global Clinical Reference, Elsevier. "Through this program, our goal is to recognize and honor those organizations that have significantly contributed to elevating positive patient outcomes through the power of information and the innovative use of technology."

The deadline for nominations is December 31, 2012. Nominations are being accepted in three institution categories:

  • Community (less than 200 beds)
  • Mid-sized (between 201 and 500 beds)
  • Large (more than 500 beds)

Applicants are asked to explain in 1,000 words or less how a particular institution is changing the way information and technology impacts patient care. Three grand prize winners will be awarded with the following:

  • $10,000 ClinicalKey Technology Grant
  • Trip for two to the HIMSS (Healthcare Information and Management Systems Society) 2013 Ann
    '/>"/>

SOURCE Elsevier
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Elsevier Launches ClinicalKey for Individual Clinicians, Providing Comprehensive Content for 41 Specialties
2. Exclusive Industry Panel for Medical Device Developers - "The Great Innovators: A Sit-Down Chat with Dr. Thomas Fogarty & Dean Kamen"
3. A Rare Feat: Two Scientists At Salk Score NIH New Innovator Awards
4. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
5. PAREXEL Chief Operating Officer Dr. Mark A. Goldberg Receives Special Recognition Award
6. QBC Diagnostics Awarded GSA Contract
7. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
8. Med Ad News Honors Healthcare Communication Agencies at 23rd Annual Manny Awards
9. Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
10. Hanger clinicians honored with 2012 Tribeca Disruptive Innovation Award
11. Northwest Bio Awarded $5.5 Million German Government Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... its Symphony® CGM System as a non-invasive, wireless continuous ... Doman , Executive Chairman and Interim CEO of Echo ... Tenth Annual Equity Conference. Mr. Doman ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... - India Drug Forecast and Market Analysis ... PharmaPoint: Atopic Dermatitis - India ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... Calif., May 5, 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: ... chief financial officer, is scheduled to present a company overview ... in Las Vegas on Tuesday, May 10th at 10:00 a.m. ... The presentation will be webcast live and can be accessed ...
... May 5, 2011 Rochester Medical Corporation (NASDAQ: ... ended March 31, 2011. The Company reported record ... for the second quarter of last year.  It also reported ... to net loss of ($351,000) or ($0.03) per diluted share ...
Cached Medicine Technology:Rochester Medical Reports Second Quarter Results 2Rochester Medical Reports Second Quarter Results 3Rochester Medical Reports Second Quarter Results 4Rochester Medical Reports Second Quarter Results 5Rochester Medical Reports Second Quarter Results 6Rochester Medical Reports Second Quarter Results 7Rochester Medical Reports Second Quarter Results 8Rochester Medical Reports Second Quarter Results 9Rochester Medical Reports Second Quarter Results 10
(Date:4/17/2014)... lost its status as the leading weapon against the ... life, with new research indicating it simply needs to ... use of the cheap anti-malarial drug chloroquine in treating ... of more than half a million people each year ... has developed resistance to chloroquine, but research carried out ...
(Date:4/16/2014)... the embryo. It begins as a glob of identical cells ... the cells of our lungs, muscles, nerves and all the ... feat of reverse tissue engineering, Stanford University researchers have begun ... to proliferate and transform into all of the specialized cells ...
(Date:4/16/2014)... 16, 2014): Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced ... of CDX-1401 in solid tumors, including long-term patient follow-up, ... (Vol 6 Issue 232). The data demonstrate robust antibody ... in patients with very advanced cancers and suggest that ...
(Date:4/16/2014)... April 16, 2014 According to a new ... average-risk patients with one to two small polyps are ... cases. This may be an appropriate target for quality ... to quantify adherence to guidelines for timing of repeat ...
(Date:4/15/2014)... , Cases of diabetes and pre-diabetes in the United States ... Johns Hopkins Bloomberg School of Public Health, with obesity apparently ... the burden of the disease has not hit all groups ... the elderly. , According to new research reported in the ...
Breaking Medicine News(10 mins):Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2
... , ... ... ... ...
... ... ... , ... , , ...
... of the blood or hematopoietic system derive from stem cell ... to all the different kinds of blood cells equally, said ... a report that appears in the current issue of the ... "While previous reports in journals have hinted at ...
... preparation (ICCBco) in the treatment of lung lesions ... experimental animal model, a research group in China ... pathological changes and pathological effect mechanism of expression ... of portal hypertensive rabbits with schistosomiasis. ...
... In tests, novel immunotherapy appears to combat mesothelioma tumors ... vaccine for the asbestos-related cancer mesothelioma is safe, according ... tested the vaccine -- which infuses a patient,s own ... on 10 patients and found that it induced an ...
... , ... ... ... , ...
Cached Medicine News:Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 2Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 3Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 4Health News:'Less Is More' with the Innovation of Avemar(R) Fermented Wheat Germ Extract 5Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 2Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 3Health News:Studies Detail Possible Benefits of omega-3 Fatty Acids for Dogs With Arthritis 4Health News:Theory of single stem cell for blood components challenged 2Health News:Treatment of portal hypertensive pulmonary lesions induced by schistosomiasis 2Health News:Vaccine for Asbestos-Related Cancer Looks Safe 2Health News:Hill-Rom Announces Second Quarter 2010 Dividend 2
... The PalmScan A2000 A-Scan [i.e., PalmScan A2000] ... biometer, which incorporates A-mode pulsed-echo ultrasound,technology, and ... the axial length (AL), anterior,chamber depth (ACD), ... This PalmScan A2000,device is also intended for ...
... TOX/See™ is a 1-step, hand-held, point-of-care device for ... in human urine. The TOX/See device can ... abused drugs in 3 to 8 minutes and ... TOX/See cassette is individually packaged to maximize convenience ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
... device for the qualitative detection of drug or ... device can detect up to nine of the ... minutes and requires only a few drops of ... maximize convenience and ease of use. TOX/See features ...
Medicine Products: